Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies

Vaccine

Volumn 28, Issue 25, 2010, Pages 4138-4144

  Duan, Hongying ^a   Struble, Evi ^a   Zhong, Lilin ^a   Mihalik, Kathleen ^a   Major, Marian ^a   Zhang, Pei ^a   Feinstone, Stephen ^a   Feigelstock, Dino ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Escape mutations; HCV; Neutralization; Vaccine

Indexed keywords

GLUTAMINE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; HISTIDINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CHIMPANZEE; CONTROLLED STUDY; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINATION; VIRUS MUTANT; VIRUS NEUTRALIZATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; IMMUNE EVASION; MUTATION; NEUTRALIZATION TESTS; PAN TROGLODYTES; VIRAL ENVELOPE PROTEINS;

EID: 77952583125     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.024     Document Type: Article

References (29)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6(1):35-47.
2. Nascimbeni M., Mizukoshi E., Bosmann M., Major M.E., Mihalik K., Rice C.M., et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 77 8 (2003) 4781-4793
3. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 101 27 (2004) 10149-10154
4. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79 10 (2005) 6023-6034
5. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartoscht B., Cosset F.L., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 104 14 (2007) 6025-6030
6. Youn J.W., Hu Y.W., Tricoche N., Pfahler W., Shata M.T., Dreux M., et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol 82 21 (2008) 10896-11905
7. Elmowalid G.A., Qiao M., Jeong S.H., Borg B.B., Baumert T.F., Sapp R.K., et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 104 20 (2007) 8427-8432
8. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 7053 (2005) 961-966
9. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12 2 (2006) 190-197
10. Zubkova I., Choi Y.H., Chang E., Pirollo K., Uren T., Watanabe H., et al. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 27 19 (2009) 2594-2602
11. Yu M.Y.W., Bartosch B., Zhang P., Guo Z.P., Renzi P.M., Shen L.M., et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 101 20 (2004) 7705-7710
12. Krawczynski K., Alter M.J., Tankersley D.L., Beach M., Robertson B.H., Lambert S., et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173 4 (1996) 822-828
13. Bartosch B., Bukh J., Meunier J.C., Granier C., Engle R.E., Blackwelder W.C., et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 100 24 (2003) 14199-14204
14. Johansson D.X., Voisset C., Tarr A.W., Aung M., Ball J.K., Dubuisson J., et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci USA 104 41 (2007) 16269-16274
15. Meunier J.C., Engle R.E., Faulk K., Zhao M., Bartosch B., Alter H., et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 102 12 (2005) 4560-4565
16. Owsianka A., Tarr A.W., Juttla V.S., Lavillette D., Bartosch B., Cosset F.L., et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79 17 (2005) 11095-11104
17. Booth J.C.L., Kumar U., Webster D., Monjardino J., and Thomas H.C. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27 1 (1998) 223-227
18. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93 26 (1996) 15394-15399
19. Torresi J., Fischer A., Grollo L., Zeng W.G., Drummer H., and Jackson D.C. Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes. Immunol Cell Biol 85 2 (2007) 169-173
20. Zhang P., Wu C.G., Mihalik K., Virata-Theimer M.L., Yu M.Y.W., Alter H.J., et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 104 20 (2007) 8449-8454
21. Zhang P., Zhong L.L., Struble E.B., Watanabe H., Kachko A., Mihalik K., et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci USA 106 18 (2009) 7537-7541
22. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., et al. Complete replication of hepatitis C virus in cell culture. Science 309 5734 (2005) 623-626
23. Widell A., Zhang Y.Y., Andersson-Gare B., and Hammarstrom L. At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulin-associated hepatitis C. Transfusion 37 3 (1997) 313-320
24. Weiner A.J., Brauer M.J., Rosenblatt J., Richman K.H., Tung J., Crawford K., et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180 2 (1991) 842-848
25. Mao Q., Ray S.C., Laeyendecker O., Ticehurst J.R., Strathdee S.A., Vlahov D., et al. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol 75 7 (2001) 3259-3267
26. Scotta C., Garbuglia A.R., Ruggeri L., Spada E., Laurenti L., Perrone M.P., et al. Influence of specific CD4+ T cells and antibodies on evolution of hypervariable region 1 during acute HCV infection. J Hepatol 48 2 (2008) 216-228
27. Feigelstock D.A., Mihalik K.B., Kaplan G., and Feinstone S.M. Increased susceptibility of Huh7 cells to HCV replication does not require mutations in RIG-I. Virol J 7 1 (2010) 44
28. Puig M., Major M.E., Mihalik K., and Feinstone S.M. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22 8 (2004) 991-1000
29. Esumi M., Zhou Y.H., Tanoue T., Tomoguri T., and Hayasaka I. In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus. Vaccine 20 25-26 (2002) 3095-3103